11.03.26 -- Advancing CGT Delivery, Regulatory Strategy With Axiom's Dr. Remo Moomiaie-Qajar

Discover a streamlined workflow that cuts reagent use and hands-on time while maintaining sequencing quality, offering an effective option for scaling up high-throughput genomics operations    .

Achieve highly consistent and precise AAV vector genome titer measurements with this optimized ddPCR protocol. This method ensures accurate dosing and optimal cell therapy potency.

Evaluate upstream options ranging from concentrated fed-batch to perfusion systems. Weighing these technical frameworks against organizational goals helps teams determine the ideal production path    .

Review closed, automated harvest, formulation, and dispensing of umbilical cord MSCs at commercial scale, with data on viability, recovery, and filling precision, including single runs.

Autologous therapies demand absolute repeatability. Examine how automated cryovial filling protects delicate cell viability while removing human error from complex manufacturing workflows    .

What changes when linearized plasmid DNA is replaced with a synthetic, cell-free template for IVT? Compare performance head to head, from enzyme kinetics to a CEPI-funded vaccine program.

Streamline your antibody production with a robust Cell Line Development strategy. Automation, analytics, and digital tools accelerate development from clone selection to commercialization.

Achieving successful extrahepatic CAR T delivery with LNPs requires addressing the unique biological and technological barriers and designing targeting approaches that leverage innovative LNP design.

Explore how integrated PCR-based workflows provide the specificity and speed necessary to safeguard your cell matrix and ensure regulatory compliance.

RNA innovation is shifting from discovery to scalable development. Explore advances in delivery, manufacturing, analytics, regulation, and commercialization driving broader therapeutic impact.

Examine how material durability directly influences fill counts, contamination risks, process reliability, and overall operational efficiency during extended pharmaceutical fill-finish runs    .

Analyze how early decisions regarding raw materials impact cell therapy development, technical transfer, and ultimate GMP readiness through practical guidance for aligning production processes    .

A new platform approach streamlines lentiviral vector design and manufacturing, boosting yield, lowering costs, and accelerating access to gene‑modified cell therapies worldwide.